The global oncology business unit of Takeda Pharmaceutical
possesses a passion for improving patients’ lives, rooted in a strong heritage
of science and innovation. We are changing expectations in science by focusing
on treatments that address forms of cancer that haven’t traditionally been the
focus of oncology R&D. This emphasis on cutting-edge science informs all
aspects of our strategy, from early-stage research and clinical programs
to our business development and collaboration approach.
Takeda’s proven commercialization capabilities allow us to
quickly respond to the diverse and dynamic needs of patients, healthcare
providers and health systems globally. We are a force of more than 2,000
dedicated oncology professionals, driven by a patient-focused entrepreneurial
spirit and commitment to agility, even as our organization grows. We
continually look for opportunities to collaborate with innovative and
forward-thinking companies to quickly bring transformative therapies to market.
Finally, we’re changing expectations about what it means to
partner with patients. We’ve redefined patient advocacy relations and our
team cares about patients in a way that influences every decision we
make. Understanding their journeys challenges us to continually bring
better medicines to market.
Every day, we come to work committed to changing
expectations through our relentless pursuit of game-changing science,
forging the right partnerships and learning from successes and failures. We
will continue to redefine paradigms and create a profound impact on patients’
lives. Our vision will not be achieved quickly or simply, but we are up to the
task: We Aspire to Cure Cancer.
